NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study Meeting Abstract
| Authors: | Johnson, M. L.; Ou, S. H. I.; Felip, E.; Baik, C.; Besse, B.; Mazieres, J.; Camidge, D. R.; Gadgeel, S.; Drilon, A.; Elamin, Y. Y.; Liu, G.; Reuss, J. E.; Kehrig, T.; Pelish, H. E.; Zhu, V.; Lin, J. J. |
| Abstract Title: | NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study |
| Meeting Title: | 2023 European Lung Cancer Congress |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 18 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2023 Mar 29-Apr 1 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-04-01 |
| Start Page: | S86 |
| End Page: | S87 |
| Language: | English |
| ACCESSION: | WOS:000995007600082 |
| PROVIDER: | wos |
| DOI: | 10.1016/S1556-0864(23)00335-0 |
| Notes: | Meeting Abstract: 81TiP -- Source: Wos |
